FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Cox John					2. Issuer Name and Ticker or Trading Symbol BIOGEN INC. [BIIB]								Relationship heck all appl Direct	cable)	g Pers	on(s) to Issu 10% Ow Other (s	ner
(Last) (First) (Middle) BIOGEN INC. 225 BINNEY STREET (Street) CAMBRIDGE MA 02142 (City) (State) (Zip)				3. Date ()2/22/2		Trans	action (Mon	th/Da	ay/Year)		X Office (give title below) below) EVP Pharmaceutical Oper & Tech						
				1. If Am	endment, I	Date o	f Original Fi	iled (N	Month/Da		6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(0		(Zip) ole I - Non-	-Derivat	ive Se	ecurities	s Acc	quired, D	ispo	osed o	f, or Be	neficia	Ily Owne				
Date				2. Transact Date (Month/Day		2A. Deemo Execution if any (Month/Da	Date,	Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)			d Securiti Benefic Owned	5. Amount of Securities Beneficially Owned Following Reported		Direct Control of the	7. Nature of Indirect Beneficial Ownership
							Code	/	Amount	(A) oi (D)	Price	Transac	ported ansaction(s) str. 3 and 4)			(Instr. 4)	
			Table II - D (e					uired, Dis , options					y Owned				
Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/\)	Cod	saction e (Instr.			6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative Security	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Cod	e V	(A)		Date Exercisable		xpiration ate	Title	Amoun or Number of Shares					
Restricted	\$0	02/22/2016		A		11,850	П	(1)	02/	/22/2019	Common	11,850	\$0	11,850)	D	

Explanation of Responses:

1. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).

> /s/ Matthew S. Gilman, Attorney-in-fact for John Cox

02/24/2016

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.